Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23677065 | 0.85 | HRH3 (0.37) | HRH3CYP2D6KCNH2 | |
| SCHEMBL22955339 | 0.83 | NCF1 (0.41) | HRH3L3MBTL1POLBALDH1A1GAA | |
| SCHEMBL18745447 | 0.81 | POLB (0.35) | HRH3L3MBTL1POLBALDH1A1GAA | |
| SCHEMBL23102131 | 0.79 | HRH3 (0.34) | HRH3 | |
| SCHEMBL19050582 | 0.77 | POLB (0.33) | L3MBTL1POLBALDH1A1GAAPKM | |
| SCHEMBL20375137 | 0.77 | POLB (0.33) | L3MBTL1POLBALDH1A1GAAPKM | |
| SCHEMBL18552498 | 0.77 | HRH3 (0.35) | HRH3 | |
| SCHEMBL20623766 | 0.77 | HRH3 (0.42) | HRH3CYP2D6KCNH2 | |
| SCHEMBL20089204 | 0.75 | POLB (0.32) | POLBALDH1A1GAACYP2D6 | |
| SCHEMBL22273429 | 0.75 | HRH3 (0.33) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11672800-B2 | Combination therapies with EHMT2 inhibitors | Epizyme, Inc. (US) | 2023-06-13 | — | — | US | disclosed |
| US-10934305-B2 | SHMT inhibitors | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2021-03-02 | — | — | US | disclosed |
| US-20200239488-A1 | SHMT Inhibitors | THE TRUSTEES OF PRINCETON UNIVERSITY | 2020-07-30 | — | — | US | disclosed |
| US-20200054635-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | Epizyme, Inc. | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934305-B2 | SHMT inhibitors | SHMT1, SHMT2, BHMT | HRH3 2529/4885L3MBTL1 669/4885POLB 984/4885 |
| US-20200239488-A1 | SHMT Inhibitors | SHMT1, SHMT2, BHMT | HRH3 3256/4885L3MBTL1 514/4885POLB 981/4885 |
| US-20200054635-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | EHMT2, BHMT, SHMT2 | HRH3 2154/4885L3MBTL1 1359/4885POLB 893/4885 |
| US-11672800-B2 | Combination therapies with EHMT2 inhibitors | EHMT2, BHMT, SHMT2 | HRH3 2154/4885L3MBTL1 1359/4885POLB 893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.